AI Verdict
PBYI has stronger fundamentals based on our AI analysis.
PCSA vs PBYI Fundamental Comparison
| Metric | PCSA | PBYI |
|---|---|---|
| Revenue | $0.0 | $228.4M |
| Net Income | $-13.6M | $31.1M |
| Net Margin | N/A | 13.6% |
| ROE | -243.2% | 23.9% |
| ROA | -173.6% | 14.4% |
| Current Ratio | 2.54x | 2.00x |
| Debt/Equity | 0.00x | 0.17x |
| EPS | $-10.36 | $0.61 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCSA vs PBYI: Frequently Asked Questions
Is PCSA or PBYI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBYI has stronger fundamentals. PCSA is rated STRONG SELL (87% confidence) while PBYI is rated BUY (72% confidence). This is not investment advice.
How does PCSA compare to PBYI fundamentally?
Processa Pharmaceuticals, Inc. has ROE of -243.2% vs PUMA BIOTECHNOLOGY, INC.'s 23.9%. Net margins are N/A vs 13.6% respectively.
Which stock pays higher dividends, PCSA or PBYI?
PCSA has a dividend yield of N/A or no dividend while PBYI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCSA or PBYI for long term?
For long-term investing, consider that PCSA has STRONG SELL rating with 87% confidence, while PBYI has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCSA vs PBYI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCSA vs PBYI, the AI consensus favors PBYI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.